Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart and Insulin Detemir.

This trial compared the glycemic control, risk of hypoglycemia, and effect on body weight of insulin detemir and NPH insulin in patients with type 1 diabetes treated with rapid-acting insulin aspart at meals.

Who Took Part

According to the abstract, 448 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

This study was a 6-month multinational open parallel-group comparison conducted at 46 centers in five countries and included 448 patients with type 1 diabetes randomized 2:1 to insulin detemir or NPH insulin, respectively.

How the Study Was Run

In design terms this was a randomized and parallel-group study.

The patients were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

The Insulin Aspart group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Carrier Proteins, Diabetes Mellitus, Type 1, Eating, Glycated Hemoglobin, Hypoglycemia and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Insulin Aspart and Insulin Detemir in 448 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page, all human trials.